Skip to main content
Sign In
 

Tomer M. Mark, MD, MSc


University of Colorado School of Medicine​
  • Clinical Director of the Plasma Cell Disorders Program
  • Associate Professor of Medicine

Contact information​

Anschutz Medical Campus
1665 Aurora Court, MS F754
Aurora, CO 80045
(720) 848 0414
tomer.mark@ucdenver.edu​

Dr. Mark earned a Bachelor of Science degree from Yale University, where he majored in Molecular Biochemistry and Biophysics. He received his Doctorate in Medicine with distinction in research from the State University of New York at Stony Brook. He then completed his residency in Internal Medicine at Beth Israel Deaconess Medical Center in Boston. Dr. Mark completed fellowship in Hematology and Medical Oncology in 2008 at Weill Cornell Medical College in New York City. He also received a Master of Science degree in Clinical Investigation from the Weill Cornell School of Graduate Sciences and completed the American Society of Hematology Clinical Research Training Institute during his fellowship training. After fellowship, Dr. Mark stayed on at Cornell and became associate director of the Multiple Myeloma Center and later director of the inpatient myeloma service at the New York Presbyterian Hospital, Cornell campus. In 2016, he joined the University of Colorado as clinical director of the plasma cell disorders program, which will cover conditions such as multiple myeloma, AL amyloidosis, light chain deposition disease, POEMS syndrome and other rare malignancies related to abnormal plasma cell function.

Dr. Mark’s research focus has been on development of novel therapies for the care of multiple myeloma, including stem cell collection protocols and transplantation conditioning regimens. He is currently a member of the International Myeloma Working Group and co-chair of the plasma cell disease committee at the Center for International Blood and Marrow Transplant Research. He has been principal investigator on multiple early to late phase clinical trials as well as the author of several book chapters on the subject of plasma cell disorders.

While clinical research is a major focus for Dr. Mark, his work also centers on providing the best patient experience possible.  He has worked with patient advocacy groups as well alongside his patients to help improve care. He has also coauthored a book with one of his patients: “Love, Olivia: A Stem Cell Transplant Story.”

  • ​Yale University, BS, 1998
  • State University of New York School of Medicine, MD with recognition in research, 2002
  • Beth Israel Deaconess Medical Center, Internship and Residency in Internal Medicine, 2005
  • Weill Cornell Medical College, Hematology and Medical Oncology Fellowship, 2008
  • Weill Cornell School of Graduate Sciences, MS, 2010

Dr. Mark’s research focus has been on development of novel therapies for the care of multiple myeloma, including stem cell collection protocols and transplantation conditioning regimens. As a clinical trialist, he has been principal investigator on phase 1 trials of new compounds for use in refractory myeloma and stem cell transplantation.  He has also led phase 2 and 3 studies designed to maximize treatment efficacy in newly diagnosed and relapsed myeloma. As every myeloma is genetically distinct, his aim to develop and deliver personalized therapy for every patient based on scientific rationale.

Peer Reviewed Articles

1) Shi H, Djikeng A, Mark T, Wirtz E, Tschudi C, Ullu E. Genetic interference in Trypanosoma brucei by heritable and inducible double-stranded RNA. RNA. 6(7):1069-76, July 2000.

2) Niesvizky R, Naib T, Christos P, Jayabalan D, Furst J, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse R, Ely S, Leonard J, Mazumdar M, Chen-Kiang S, Coleman M. Lenalidomide-induced myelosuppression is associated with renal dysfunction: Toxicity evaluation of treatment naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol. 2007 Sep;138(5):640-3.

3) Mark T, Niesvizky R. The treatment of multiple myeloma and myelodysplastic syndromes with immunomodulatory agents. US Oncol Disease. 2007.Vol 2:26-30.

4) Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, DeSancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Rambo A. Leonard J, Jayabalan D, Coleman M. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia and Lymphoma. 2007 Dec;48(12):2330-7.

5) Niesvizky R, Jayabalan D, Christos P, Furst J, Naib T, Ely S, Jalbrzikowski J, Pearse R, Zafar F, Pekle K, Lent R, Mark T, Cho H, Shore T, Tepler J, Harpel J, Schuster M, Mathew S, Leonard J, Mazumdar M, Chen-Kiang S, Coleman M. BiRD (Biaxin®[clarithromycin]/ Revlimid®[lenalidomide]/ dexamethasone) Combination Therapy Results in High Complete and Overall Response Rates in Treatment-Naïve Symptomatic Multiple Myeloma. Blood. 2008 Feb 1;111(3):1101-9.

6) Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, Pearse RN, Harpel J, Shore T, Schuster MW, Leonard JP, Christos PJ, Coleman M, Niesvizky R. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8.

7) Mark T, Jayabalan D, Pearse R. et al. Atypical Serum Immunofixation Patterns are frequently associated with immunomodulatory therapy and herald complete response in multiple myeloma. British Journal of Hematology. 2008. Dec;143(5):654-60.

8) Mark T, Niesvizky R, Coleman M. The Novel Agents in Multiple Myeloma: An Exciting Saga. Cancer. 2008. Nov;115(2):236-42.

9) Mark T, Martin P, Leonard JP, Niesvizky R. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2009. Jan;18(1):99-104.

10) Mark T, Coleman M, Niesvizky R. Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma. Asia-Pacific Journal of Oncology & Hematology. 2009;1(2):1-5.

11) Niesvizky R, Coleman M, Mark T. Best Practices in the Management of Newly Diagnosed Multiple Myeloma Patients Who Will Not Undergo Transplant. Oncology. 2010;24(3):14-21.

12) Gay F, Rajkumar SV, Jayabalan D, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard JP, Lacy MQ, Cheng-Kiang S, Roy V, Coleman M, Lust JA, Witzig TE,  Fonseca R, Kyle RA, Greipp PR, Stewart AK, and Niesvizky R. Superiority Of Clarithromycin (Biaxin)-Lenalidomide-low-dose dexamethasone (BiRd) Versus Lenalidomide-low-dose Dexamethasone (Rd) As Initial Therapy for Newly Diagnosed Multiple Myeloma. Am J Hematol. 2010 Sep;85(9):664-9.

13) Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove J, Wright JJ, Chen-Kiang S and  Sparano JA. Phase II trial of the histone deacetylase inhibitor romidepsin for the treatment of  refractory multiple myeloma. Cancer. 2011 Jan;117(2):336-42.

14) Cushing M, Kawaguchi K, Friedman KD, and Mark T. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. Transfusion. 2012 Jul;52(7):1535-41

15) Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RR, Ruan J, Pearse RN, Coleman M, Mark T, Leonard JP, and Gergis U. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012 Apr;87(4):433-5.

16) Dimopoulos, M, Terpos E, Goldschmidt H, Alegre A, Mark T, and Niesvizky R. Treatment with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Renal Impairment. Cancer Treatment Reviews. 2012 Dec;38(8):1012-9.

17) Richardson PG, Mark T, and Lacy MQ. Pomalidomide: New immunomodulatory agent with potent antiproliferative effects. Crit Rev Oncol Hematol. 2013 Jun 17.

18) Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R.  BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013 Jan 8.

19) Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T. A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma. Biol Blood Marrow Transplant. 2013 Feb 20.

20) Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, Stern J, Christos PJ, Mathews L, Shore TB, Zafar F, Pekle K, Xiang Z, Ely S, Skerret D, Chen-Kiang S, Coleman M, Lane ME. Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. Clin Cancer Res. 2013 Mar 1.

21) Forsberg PA, Mark TM. Pomalidomide in the treatment of relapsed multiple myeloma. Future Oncol. 2013 Jul;9(7):939-48.

22) Gergis U, Roboz G, Shore T, Ritchie E, Mayer S, Wissa U, McKenna M, Christos P, Pearse R, Mark T, Scandura J, van Besien K, Feldman E. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013 Jul;19(7):1040-5.

23) Meadows JP, Mark TM. Management of Double-Refractory Multiple Myeloma. Curr Hematol Malig Rep. 2013 Dec;8(4):253-60.

24) Gergis U, Mayer S, Gordon B, Mark T, Pearse R, Shore T, Van Besien K. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone Marrow Transplant. 2014 Feb 17.

25) Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R, Pearse RN, Zafar F, Pekle K, Jayabalan D, Ely S, Coleman M, Chen-Kiang S, Niesvizky R. T-BiRD (thalidomide, clarithromycin, lenalidomide and dexamethasone) therapy in newly diagnosed, symptomatic multiple myeloma. Leuk Lymphoma. 2014 Feb 28. 

26) Mark TM, Coleman M, Niesvizky R. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. Leuk Res. 2014 Mar 13.

27) Khagi Y, Mark TM. Potential Role of Daratumumab in the Treatment of Multiple Myeloma. Onco Targets Ther. 2014 Jun 18;7:1095-100.

28) Preeshagul IR, Van Besien K, Mark TM. Controversies in Multiple Myeloma: to Transplant or Not? Curr Hematol Malig Rep. 2014 Aug 22.

29) Storch E, Mark TM, Avecilla S, Pagan C, Rhodes J, Shore T, van Besien K, Cushing M. A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. Transfusion. 2015 Mar 21.

30) Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE, Walsh TJ, Gergis U. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Jul 3.

31) Runcie KD, Mark TM. Novel Induction Regimens in Multiple Myeloma. Curr Hematol Malig Rep. 2015 Aug 15.

32​) Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Aug 24.

33) D’Souza A, Dispenzieri A, Wirk B, Zhang M-J, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter G, Robert, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology. 2015 Nov 10;33(32):3741-9.

34) Novikov A, Holzer H, DeSimone RA, Abu-Zeinah G, Pisapia DJ, Mark TM, Pastore RD. Diaphragmatic Amyloidosis Causing Respiratory Failure: A Case Report and Review of Literature. Case Reports in Oncological Medicine. 2015; 4.

35) Mark TM, Coleman M. It's Time to Take Clarithromycin Seriously in Multiple Myeloma. Acta Haematol 2016;135:101-102.

36) Mark TM, Pekle K. Clonal Plasma Cells Keep Strange Company. Leuk Lymphoma. 2016 Jan 4:1-2.

37) Lee HC, Mark T, Shah J. Practical Approaches to Management of Dual Refractory Multiple Myeloma. Curr Hematol Malig Rep. 2016; Feb 22.

38) G​ergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K.  Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016; Feb 18.

39) Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J25, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016 Aug 2: S1083-8791(16)30223-3.

40) van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T. Cord blood chimerism and relapse after haplo-cord transplantation. Leuk Lymphoma. 2016 Jun 23:1-10.

41) Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66.

Books

1) Mark T, Pearse RN. Pathophysiology of Bone Disease in Multiple Myeloma. Myeloma Therapy: Pursuing the Plasma Cell.  Edited by: S. Lonial. Humana Press, Totowa, NJ. December 2008. pp 435-454. 

2) Chin O, Mark T. Love, Olivia. WestBow Press. February 2012.

3) Ely S, Niesvizky R, Mark T. B-cell immunoproliferative disorders, including multiple myeloma and primary amyloidosis. Knowles’ Neoplastic Hematopathology, 3rd edition. Lippincott Williams & Wilkins. December 2013. ​